Schonfeld Strategic Advisors’s Coherus Oncology CHRS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-39,268	Closed	-$376K	–	2635
2022 Q3	$376K	Buy	39,268 +7,614	+24%	+$77K	﹤0.01%	1944
2022 Q2	$229K	Buy	+31,654	New	+$275K	﹤0.01%	1815
2022 Q1	–	Sell	-23,000	Closed	-$367K	–	2618
2021 Q4	$367K	Buy	+23,000	New	+$402K	﹤0.01%	1427
2021 Q2	–	Sell	-19,103	Closed	-$279K	–	1988
2021 Q1	$279K	Buy	+19,103	New	+$324K	﹤0.01%	1364
2020 Q2	–	Sell	-24,952	Closed	-$405K	–	1275
2020 Q1	$405K	Sell	24,952 -35,796	-59%	-$661K	0.03%	653
2019 Q4	$1.09M	Buy	+60,748	New	+$1.12M	0.03%	486
2019 Q3	–	Sell	-79,600	Closed	-$1.76M	–	1042
2019 Q2	$1.76M	Sell	79,600 -177,100	-69%	-$3.08M	0.06%	313
2019 Q1	$3.5M	Buy	+256,700	New	+$3.42M	0.12%	226

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Schonfeld Strategic Advisors's CHRS Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 39,268 shares — an estimated $376K sold.

Schonfeld Strategic Advisors first reported a position in CHRS in Q1 2019 and held it in 8 quarters. The position peaked at $3.5M in Q1 2019. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

Schonfeld Strategic Advisors reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 39,268 Coherus Oncology shares in Q4 2022, an estimated $376K.
Schonfeld Strategic Advisors first reported a position in Coherus Oncology in Q1 2019 and held it in 8 quarters.
Schonfeld Strategic Advisors's Coherus Oncology position peaked at $3.5M in Q1 2019.
161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.